MNOV MediciNova, Inc.
USHealthcareAs of 2026-07-09 16:00
Why MNOV matters now
MediciNova, Inc. (MNOV) is a US stock in Healthcare. The latest InvestLog snapshot shows $1.38 with -1.43% on the session and $67.9M in market capitalization; recent performance reads 1-month -4.35% and YTD +0.76%.
The latest financial table shown here is Q1 2026, with revenue of $187.0K, net income of $-2.6M, and EPS of $-0.05. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -14.6%.
The latest indexable market news headline is "MediciNova CEO Provides Shareholder Update" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $—; recent insider activity includes IWAKI YUICHI filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
1.65
P/S
108.90
EV/EBITDA
-3.23
DCF Value
$0.61
FCF Yield
-14.6%
Div Yield
0.0%
Margins & Returns
Gross Margin
15.2%
Operating Margin
-2164.8%
Net Margin
-1964.3%
ROE
-27.3%
ROA
-27.4%
ROIC
-6.3%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $187.0K | $-2.6M | $-0.05 |
| Q4 2025 | $151.7K | $-2.8M | $-0.05 |
| FY 2025 | $409.7K | $-12.0M | $-0.24 |
| Q3 2025 | $123.3K | $-3.1M | $-0.06 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$—
Target (Median)
$—
Target Range
$— - $—
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.62
MediciNova, Inc. is a biopharmaceutical firm dedicated to discovering and advancing innovative small molecule therapies for severe illnesses where current treatments are insufficient within the United States. Its robust development pipeline features MN-166 (ibudilast), an oral agent with both anti-inflammatory and neuroprotective properties, currently being investigated for a range of neurological conditions. These include primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and various forms of substance dependence and addiction. The company's portfolio also comprises MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist aimed at treating acute asthma attacks; MN-001 (tipelukast), an orally available small molecule designed for fibrotic disorders like nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent intended for solid tumor oncology. MediciNova has established strategic partnerships with companies such as Kissei Pharmaceutical Co., Ltd., Kyorin Pharmaceutical Co., Ltd., Angiogene Pharmaceuticals Ltd., and Meiji Seika Kaisha Ltd. Established in 2000, the company's headquarters are situated in La Jolla, California.